The short duration (4 days) and limited statistical power (10 adults and eight children) of the study of Pieper et al. make such a strong message rather questionable [4] . Indeed, only 4 days after starting sevelamer, none of the CsA parameters (measured by Cedia and FPIA assays) was completely stable: the area under the curve (AUC) decreased from 3547±660 to 3230±612 ng/h/ml, C max decreased from 955±193 to 855±272 ng/ml and T max increased from 1.3 to 1.5 h. In addition, when measured with polyclonal antibodies, the CsA levels decreased significantly and, among its primary metabolites determined by HPLC, the AUC and C max of AM1-which also has an immunosuppressive action [5]-decreased significantly by 30 and 25%, respectively. Despite these observations, the authors conclude that 'sevelamer intake for several days does not significantly influence CsA kinetics'. Based on their data, this conclusion appears at least premature, especially if the risk of transplant rejection due to insufficient immunosuppression is considered [6] . Great caution in the use of sevelamer in transplanted patients is still warranted until a careful long-term, large size study on the potential interaction of sevelamer with CsA solves the question.
